Midazolam Accord (Midazolam)

Midazolam enhances the activity of the neurotransmitter GABA at the GABA‑A receptor, increasing chloride ion flow into neurons. This heightened inhibition reduces neuronal firing, producing sedative, anxiolytic, muscle‑relaxant, and anticonvulsant effects.

The specific dose of Midazolam Accord is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, route of administration, and therapeutic goal. Healthcare professionals set the appropriate regimen for each individual case.

Midazolam is classified as a pregnancy‑category drug with limited safety data. It should only be used when the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should discuss risks with their healthcare provider, as the drug can be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Midazolam offers a rapid onset and short duration of action compared with longer‑acting benzodiazepines like diazepam. Its injectable form allows precise control during procedures, whereas oral agents may have slower absorption. It is often preferred for procedural sedation and emergency seizure control.

Midazolam Accord should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain potency and sterility.

Midazolam Accord is administered by a qualified healthcare professional via intramuscular, intravenous, or rectal routes, depending on the clinical situation. The route is selected to achieve the desired speed and depth of sedation or seizure control.

The most serious risks include respiratory depression, severe hypotension, paradoxical reactions such as agitation or hallucinations, and rare anaphylactic responses. Continuous monitoring of breathing and cardiovascular status is essential during and after administration.

Midazolam should be avoided in patients with known hypersensitivity to benzodiazepines, severe respiratory insufficiency, acute narrow‑angle glaucoma, or those taking high‑dose opioids without appropriate monitoring. Clinicians must evaluate each patient’s medical history before use.